Anastrozole | List of Frontiers open access articles

Original Research

Published on 02 Apr 2024

Anastrozole monotherapy further improves near-adult height after the initial combined treatment with leuprorelin and anastrozole in early-maturing girls with compromised growth prediction: results from the second phase of the GAIL study

in Pediatric Endocrinology

Dimitrios T. Papadimitriou
Eleni Dermitzaki
Panagiotis Christopoulos
Sarantis Livadas
Ioanna N. Grivea
George Mastorakos

Frontiers in Endocrinology

doi 10.3389/fendo.2024.1366970

7,675 views
1 citation

Original Research

Published on 12 Sep 2017

Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole

in Experimental Pharmacology and Drug Discovery

Vincenzo Monda
Gelsy A. Lupoli
Giovanni Messina
Rosario Peluso
Annalisa Panico
Ines Villano
Monica Salerno
Francesco Sessa
Francesca Marciello
Fiorenzo Moscatelli

Frontiers in Pharmacology

doi 10.3389/fphar.2017.00632

8,235 views
15 citations

Case Report

Published on 02 Mar 2023

Case Report: Anastrozole as a monotherapy for pre-pubertal children with non-classic congenital adrenal hyperplasia

in Pediatric Endocrinology

Sandy C. Liu
Malavika Suresh
Mutaz Jaber
Yesica Mercado Munoz
Kyriakie Sarafoglou

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1101843

8,667 views
7 citations

Original Research

Published on 14 May 2025

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database

in Pharmacoepidemiology

Yuan-Yuan Wu
Qiong-Lian Huang
Zhan-Yang Luo
Xiao-Yun Song
You-Yang Shi
Jin-Zhou Zheng
Sheng Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1529342

4,191 views
3 citations

Case Report

Published on 01 Feb 2024

Aromatase inhibitor-induced arthralgia ameliorated by Mediterranean diet and active lifestyle guided by continuous glucose monitoring: a case report and review of the literature

in Breast Cancer

Kalin L. Wilson
Richard E. Grewelle
Tanya Gupta
Sun H. Kim
Tamiko R. Katsumoto

Frontiers in Oncology

doi 10.3389/fonc.2024.1189287

5,674 views
1 citation

Review

Published on 16 Dec 2021

Should Skeletal Maturation Be Manipulated for Extra Height Gain?

in Pediatric Endocrinology

Jan M. Wit

Frontiers in Endocrinology

doi 10.3389/fendo.2021.812196

44,846 views
24 citations

Review

Published on 17 Jun 2025

Update in the clinical utilization of chemoprevention for breast cancer: a narrative review

in Breast Cancer

Razan Mansour
Mahmoud Abunasser
Baha’ Sharaf
Hikmat Abdel-Razeq

Frontiers in Oncology

doi 10.3389/fonc.2025.1435253

3,353 views
4 citations

Case Report

Published on 30 Nov 2022

Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review

in Breast Cancer

Zhaohui Chu

Frontiers in Oncology

doi 10.3389/fonc.2022.984454

4,019 views
4 citations

Original Research

Published on 17 Jan 2022

Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis

in Breast Cancer

Tao He
Xu Li
Jiayuan Li
Zhu Wang
Yuan Fan
Xiusong Li
Zhoukai Fu
Yunhao Wu
Qing Lv
Ting Luo

Frontiers in Oncology

doi 10.3389/fonc.2021.670897

5,721 views
14 citations

Case Report

Published on 23 Aug 2022

Case report: Fluctuating tumor markers in a boy with gonadotropin-releasing hormone-independent precocious puberty induced by a pineal germ cell tumor

in Pediatric Endocrinology

Alessandro Cattoni
Assunta Albanese

Frontiers in Pediatrics

doi 10.3389/fped.2022.940656

4,311 views
8 citations

Original Research

Published on 23 Oct 2023

Non-aromatizable androgens modulate the lipopolysaccharide induced expression of the P2X7 receptor in human adipocytes

in Inflammation Pharmacology

Angelo Di Vincenzo
Marnie Granzotto
Marika Crescenzi
Roberto Vettor
Marco Rossato

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1251035

2,279 views
1 citation

Original Research

Published on 06 Feb 2023

First use of antineoplastic agents in women with breast cancer in the state of Rio de Janeiro, Brazil

in Pharmacoepidemiology

Ranailla Lima Bandeira dos Santos
Claudia Garcia Serpa Osorio-de-Castro
Mario Jorge Sobreira-da-Silva
Vera Lúcia Edais Pepe

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1069505

2,571 views
1 citation

Original Research

Published on 10 Feb 2022

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

in Breast Cancer

Sara M. Tolaney
Muralidhar Beeram
J. Thaddeus Beck
Alison Conlin
E. Claire Dees
Shannon L. Puhalla
Brent N. Rexer
Howard A. Burris
Komal Jhaveri
Teresa Helsten

Frontiers in Oncology

doi 10.3389/fonc.2021.810023

13,257 views
16 citations

Original Research

Published on 15 Jun 2021

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

in Pharmacogenetics and Pharmacogenomics

Daniel L. Hertz
Karen Lisa Smith
Yuhua Zong
Christina L. Gersch
Andrea M. Pesch
Jennifer Lehman
Amanda L. Blackford
N. Lynn Henry
Kelley M. Kidwell
James M. Rae

Frontiers in Genetics

doi 10.3389/fgene.2021.662734

4,289 views
14 citations

Clinical Trial

Published on 15 May 2020

Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects

in Endocrinology of Aging

Georgia Colleluori
Rui Chen
Christie G. Turin
Francesca Vigevano
Clifford Qualls
Biju Johnson
Sanjay Mediwala
Dennis T. Villareal
Reina Armamento-Villareal

Frontiers in Endocrinology

doi 10.3389/fendo.2020.00277

26,311 views
37 citations

Systematic Review

Published on 30 May 2022

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis

in Pharmacology of Anti-Cancer Drugs

Hao Liao
Wendi Pei
Jianxin Zhong
Bin Shao
Xiaoran Liu
Yaxin Liu
Jiayang Zhang
Hope S. Rugo
Huiping Li

Frontiers in Pharmacology

doi 10.3389/fphar.2022.886954

5,084 views
2 citations

Articles

Anastrozole monotherapy further improves near-adult height after the initial combined treatment with leuprorelin and anastrozole in early-maturing girls with compromised growth prediction: results from the second phase of the GAIL study

Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole

Case Report: Anastrozole as a monotherapy for pre-pubertal children with non-classic congenital adrenal hyperplasia

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database

Aromatase inhibitor-induced arthralgia ameliorated by Mediterranean diet and active lifestyle guided by continuous glucose monitoring: a case report and review of the literature

Should Skeletal Maturation Be Manipulated for Extra Height Gain?

Update in the clinical utilization of chemoprevention for breast cancer: a narrative review

Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review

Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis

Case report: Fluctuating tumor markers in a boy with gonadotropin-releasing hormone-independent precocious puberty induced by a pineal germ cell tumor

Non-aromatizable androgens modulate the lipopolysaccharide induced expression of the P2X7 receptor in human adipocytes

First use of antineoplastic agents in women with breast cancer in the state of Rio de Janeiro, Brazil

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis